Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 607079, 9 pages
http://dx.doi.org/10.1155/2015/607079
Review Article

An Update on Renal Artery Denervation and Its Clinical Impact on Hypertensive Disease

Department of Cardiology, Blacktown Mount Druitt Hospital, Blacktown Road, Blacktown, NSW 2148, Australia

Received 27 February 2015; Accepted 1 May 2015

Academic Editor: Giuseppe Biondi-Zoccai

Copyright © 2015 Aditya Bhat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” JAMA, vol. 289, no. 19, pp. 2560–2572, 2003. View at Google Scholar
  2. S. S. Franklin, M. G. Larson, S. A. Khan et al., “Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study,” Circulation, vol. 103, no. 9, pp. 1245–1249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies,” The Lancet, vol. 360, no. 9349, pp. 1903–1913, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Whitworth, “World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension,” Journal of Hypertension, vol. 21, no. 11, pp. 1983–1992, 2003. View at Publisher · View at Google Scholar
  5. J. Stamler, R. Stamler, and J. D. Neaton, “Blood pressure, systolic and diastolic, and cardiovascular risks. US population data,” Archives of Internal Medicine, vol. 153, no. 5, pp. 598–615, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Lawes, S. V. Hoorn, and A. Rodgers, “Global burden of blood-pressure-related disease, 2001,” The Lancet, vol. 371, no. 9623, pp. 1513–1518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. G. McGovern, G. L. Burke, J. M. Sprafka, S. Xue, A. R. Folsom, and H. Blackburn, “Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The minnesota heart survey,” The Journal of the American Medical Association, vol. 268, no. 6, pp. 753–759, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Collins and S. MacMahon, “Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease,” British Medical Bulletin, vol. 50, no. 2, pp. 272–298, 1994. View at Google Scholar · View at Scopus
  9. C. Rosendorff, H. R. Black, C. P. Cannon et al., “Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention,” Circulation, vol. 115, no. 21, pp. 2761–2788, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension,” Journal of Hypertension, vol. 31, no. 10, pp. 1925–1938, 2013. View at Google Scholar
  11. E. C. Yiannakopoulou, J. S. Papadopulos, D. V. Cokkinos, and T. D. Mountokalakis, “Adherence to antihypertensive treatment: a critical factor for blood pressure control,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 12, no. 3, pp. 243–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. O. A. Carretero and S. Oparil, “Essential hypertension. Part I: definition and etiology,” Circulation, vol. 101, no. 3, pp. 329–335, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. A. S. Zanchetti, “Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension,” Circulation, vol. 56, no. 5, pp. 691–698, 1977. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Kon, “Neural control of renal circulation,” Mineral and Electrolyte Metabolism, vol. 15, no. 1-2, pp. 33–43, 1989. View at Google Scholar · View at Scopus
  15. V. M. Campese, “Neurogenic factors and hypertension in renal disease,” Kidney International, Supplement, vol. 57, no. 75, pp. S2–S6, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Julius, “The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension,” Clinical and Experimental Hypertension, vol. 18, no. 3-4, pp. 305–321, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Langewitz, H. Rüddel, and H. Schächinger, “Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress,” American Heart Journal, vol. 127, no. 1, pp. 122–128, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Grassi, B. M. Cattaneo, G. Seravalle, A. Lanfranchi, and G. Mancia, “Baroreflex control of sympathetic nerve activity in essential and secondary hypertension,” Hypertension, vol. 31, no. 1, pp. 68–72, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kara, K. Narkiewicz, and V. K. Somers, “Chemoreflexes—physiology and clinical implications,” Acta Physiologica Scandinavica, vol. 177, no. 3, pp. 377–384, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Esler, “The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension,” Experimental Physiology, vol. 96, no. 7, pp. 611–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. L. Osborn, G. F. DiBona, and M. D. Thames, “Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation,” Journal of Pharmacology and Experimental Therapeutics, vol. 216, no. 2, pp. 265–269, 1981. View at Google Scholar · View at Scopus
  22. M. Esler, G. Jennings, and G. Lambert, “Noradrenaline release and the pathophysiology of primary human hypertension,” American Journal of Hypertension, vol. 2, no. 3, part 2, pp. 140S–146S, 1989. View at Google Scholar · View at Scopus
  23. P. A. Sarafidis and G. L. Bakris, “Resistant hypertension: an overview of evaluation and treatment,” Journal of the American College of Cardiology, vol. 52, no. 22, pp. 1749–1757, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research,” Circulation, vol. 117, no. 25, pp. e510–e526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. D. Pierdomenico, D. Lapenna, A. Bucci et al., “Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension,” The American Journal of Hypertension, vol. 18, no. 11, pp. 1422–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. H. Smithwick and J. E. Thompson, “Splanchnicectomy for essential hypertension; results in 1,266 cases,” The Journal of the American Medical Association, vol. 152, no. 16, pp. 1501–1504, 1953. View at Publisher · View at Google Scholar · View at Scopus
  27. V. M. Campese and E. Kogosov, “Renal afferent denervation prevents hypertension in rats with chronic renal failure,” Hypertension, vol. 25, no. 4, part 2, pp. 878–882, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. R. E. Katholi, S. R. Winternitz, and S. Oparil, “Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat,” The Journal of Clinical Investigation, vol. 69, no. 1, pp. 55–62, 1982. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Tomoda, G. Bergström, R. G. Evans, and W. P. Anderson, “Evidence for decreased structurally determined preglomerular resistance in the young spontaneously hypertensive rat after 4 weeks of renal denervation,” Journal of Hypertension, vol. 15, no. 10, pp. 1187–1195, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Krum, M. P. Schlaich, P. A. Sobotka et al., “Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study,” The Lancet, vol. 383, no. 9917, pp. 622–629, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. Symplicity HTN-1 Investigators, “Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months,” Hypertension, vol. 57, no. 5, pp. 911–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. Symplicity HTN-2 Investigators, M. D. Esler, H. Krum, P. A. Sobotka, M. P. Schlaich, and R. E. Schmieder, “Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial,” The Lancet, vol. 376, no. 9756, pp. 1903–1909, 2010. View at Publisher · View at Google Scholar
  33. B. P. Geisler, B. M. Egan, J. T. Cohen et al., “Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension,” Journal of the American College of Cardiology, vol. 60, no. 14, pp. 1271–1277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. G. Worthley, C. P. Tsioufis, M. I. Worthley et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial,” European Heart Journal, vol. 34, no. 28, pp. 2132–2140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. S. G. Worthly, C. P. Tsioufis, M. I. Worthley et al., “St. Jude medical study of EnligHTN I renal denervation system: 18-month data,” in Proceedings of the 25th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium, San Francisco, Calif, USA, October 2013.
  36. M. Taborsky, M. Lazarova, J. Vaclavik, and D. Richter, “The effect of renal denervation in patients with advanced heart failure: the OLOMOUC I study,” in Proceedings of the European Society of Cardiology Congress, Munich, Germany, August 2012.
  37. M. C. Brandt, F. Mahfoud, S. Reda et al., “Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension,” Journal of the American College of Cardiology, vol. 59, no. 10, pp. 901–909, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. Davies, C. H. Manisty, R. Petraco et al., “First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study,” International Journal of Cardiology, vol. 162, no. 3, pp. 189–192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. C. S. Zuern, C. Eick, K. D. Rizas et al., “Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension,” Journal of the American College of Cardiology, vol. 62, no. 22, pp. 2124–2130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. D. L. Bhatt, D. E. Kandzari, W. W. O'Neill et al., “A controlled trial of renal denervation for resistant hypertension,” The New England Journal of Medicine, vol. 370, no. 15, pp. 1393–1401, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Rodriguez-Leor, J. Bonet, and A. Bayes-Genis, “Renal denervation for resistant hypertension,” The New England Journal of Medicine, vol. 371, no. 2, pp. 182–183, 2014. View at Publisher · View at Google Scholar
  42. J. M. Flack, D. A. Sica, G. Bakris et al., “Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement,” Hypertension, vol. 56, no. 5, pp. 780–800, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Mancia, R. Fagard, K. Narkiewicz et al., “2013 ESH-ESC guidelines for the management of hypertension,” European Heart Journal, vol. 34, no. 28, pp. 2159–2219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. D. L. Bhatt and G. L. Bakris, “Renal denervation for resistant hypertension,” The New England Journal of Medicine, vol. 371, no. 2, p. 184, 2014. View at Google Scholar